XTL Biopharmaceuticals Lt...
(XTLB)
undefined
undefined%
At close: undefined
Company Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd.
| Country | IL |
| IPO Date | Sep 1, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Shlomo Spokone Shalev |
Contact Details
Address: 5 Badner Street Ramat Gan, IL | |
| Website | https://www.xtlbio.com |
Stock Details
| Ticker Symbol | XTLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023549 |
| CUSIP Number | 98386D307 |
| ISIN Number | US98386D3070 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shlomo Spokone Shalev | Chief Executive Officer & Director |
| Itay Weinstein CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Oct 15, 2024 | 6-K | Filing |
| Aug 14, 2024 | 6-K | Filing |
| Jul 22, 2024 | 6-K | Filing |
| Jun 12, 2024 | 6-K | Filing |
| Jun 05, 2024 | 6-K | Filing |
| May 13, 2024 | 6-K | Filing |
| Apr 30, 2024 | 6-K | Filing |
| Apr 30, 2024 | 20-F | Filing |